Corteva, Inc. CTVA
Composite 55/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 37/100 — a moderate mark against it.
Balance-sheet strength ranks 72/100 — a moderate point in its favour. Growth ranks 67/100 — a moderate point in its favour. Momentum ranks 64/100 — a moderate point in its favour.
Valuation ranks 37/100 — a moderate mark against it. Income ranks 42/100 — a slight mark against it. Quality ranks 47/100 — a slight mark against it.
What the company does Corteva, Inc. (CTVA) is an agricultural inputs business with two segments: Seed (germplasm, traits, digital tools) and Crop Protection (herbicides, insecticides, nitrogen stabilizers). It serves global markets, emphasizing yield optimization and pest/disease resistance.
Key financials Margins: gross 49.5%, operating 30.1%, net 5.7%. ROE 4.3%, ROA 4.5%, ROCE 6.5%. Revenue growth 2.9%, EPS growth 30.8%. Debt/equity 0.19, interest coverage 11.43, current ratio 1.52. Dividend yield 0.8%, payout 19.0%.
Stock health SideraVia scores: Overall 55.4 (Weak quality, fairly valued), Quality 47.1, Growth 66.9, Strength 72.2, Valuation 37.4, Momentum 63.9, Income 41.5. Piotroski F-Score 7/9, Altman Z 2.72. RSI(14) 69.10; 3m +13.34%, 6m +11.64%, 12m +19.65%.
Price vs fair value CTVA trades at a discount of 5.20% versus the analyst mean target of 92.30. - New corn trait launch by Vylor may pressure CTVA’s market share (Vylor Launches a New Era in Corn: Industry-First Yield and Yield Stability Trait). - Comparative valuation piece questions CTVA’s relative attractiveness (DOLE or CTVA: Which Is the Better Value Stock Right Now?). - Forward P/E 21.93 vs trailing 47.05 signals earnings recovery expectations. - Valuation percentile 37.4/100 indicates below-median pricing relative to peers.
Looking forward Forward PEG 0.19 and EV/EBITDA 18.16 suggest earnings growth is priced for a rebound. Weak quality scores (47.1) temper enthusiasm despite momentum and growth metrics. Execution on trait innovation and margin recovery will drive near-term performance.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.